Therefore, developing a novel P-gp inhibitor or antitumor drug that is not a P-gp substrate to avoid chemotherapy drug efflux and increase drug sensitivity is of great significance for tumor-resistant patients. The gene discussed is PGP; the disease is neoplasm.